Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-word experience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis.Areas covered: In this narrative review, we address the safety of intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, co-existing brain tumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting of acute cerebral ischemia.Expert opinion: The present narrative review summarizing 20 years of clinical experience with IVT for AIS highlights that many of the current guidelines and protocols should be adjusted to accommodate recent data from registries and real-world experience underscoring the safety of IVT in numerous conditions of AIS that were originally considered as relative or absolute contraindications for administration of IV-tPA.

Original languageEnglish (US)
Pages (from-to)845-864
Number of pages20
JournalExpert Opinion on Drug Safety
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Stroke
Safety
Tissue Plasminogen Activator
Intravenous Administration
Off-Label Use
Intracranial Arteriovenous Malformations
Expert Testimony
Intracranial Aneurysm
Brain Ischemia
Thoracic Aorta
Brain Neoplasms
Fistula
Registries
Dissection
Arteries
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions. / Tsivgoulis, Georgios; Safouris, Apostolos; Alexandrov, Andrei.

In: Expert Opinion on Drug Safety, Vol. 14, No. 6, 01.06.2015, p. 845-864.

Research output: Contribution to journalReview article

@article{582100c49a704dda9b6e7e4d579f3d7b,
title = "Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions",
abstract = "Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-word experience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis.Areas covered: In this narrative review, we address the safety of intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, co-existing brain tumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting of acute cerebral ischemia.Expert opinion: The present narrative review summarizing 20 years of clinical experience with IVT for AIS highlights that many of the current guidelines and protocols should be adjusted to accommodate recent data from registries and real-world experience underscoring the safety of IVT in numerous conditions of AIS that were originally considered as relative or absolute contraindications for administration of IV-tPA.",
author = "Georgios Tsivgoulis and Apostolos Safouris and Andrei Alexandrov",
year = "2015",
month = "6",
day = "1",
doi = "10.1517/14740338.2015.1032242",
language = "English (US)",
volume = "14",
pages = "845--864",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions

AU - Tsivgoulis, Georgios

AU - Safouris, Apostolos

AU - Alexandrov, Andrei

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-word experience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis.Areas covered: In this narrative review, we address the safety of intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, co-existing brain tumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting of acute cerebral ischemia.Expert opinion: The present narrative review summarizing 20 years of clinical experience with IVT for AIS highlights that many of the current guidelines and protocols should be adjusted to accommodate recent data from registries and real-world experience underscoring the safety of IVT in numerous conditions of AIS that were originally considered as relative or absolute contraindications for administration of IV-tPA.

AB - Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-word experience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis.Areas covered: In this narrative review, we address the safety of intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, co-existing brain tumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting of acute cerebral ischemia.Expert opinion: The present narrative review summarizing 20 years of clinical experience with IVT for AIS highlights that many of the current guidelines and protocols should be adjusted to accommodate recent data from registries and real-world experience underscoring the safety of IVT in numerous conditions of AIS that were originally considered as relative or absolute contraindications for administration of IV-tPA.

UR - http://www.scopus.com/inward/record.url?scp=84929572387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929572387&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1032242

DO - 10.1517/14740338.2015.1032242

M3 - Review article

VL - 14

SP - 845

EP - 864

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -